Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Cytogenetic Study of Ocular Melanoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2016 by Jonsson Comprehensive Cancer Center
Sponsor:
Information provided by (Responsible Party):
Jonsson Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT00344799
First received: June 26, 2006
Last updated: July 5, 2016
Last verified: July 2016
  Purpose
Patients who are diagnosed with choroidal melanoma and undergo I-125 plaque or enucleation surgery consent to participate in the study. A tumor sample taken during surgery is studied in the lab for genetic features. These features and features of subjects' clinical course are recorded. Analysis of the data may identify genetic features that are indicative of prognostic factors including risk of metastasis.

Condition
Choroidal Melanoma

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Molecular and Cytogenetic Studies of Ocular Melanoma

Resource links provided by NLM:


Further study details as provided by Jonsson Comprehensive Cancer Center:

Estimated Enrollment: 200
Study Start Date: April 2005
Estimated Primary Completion Date: July 2017 (Final data collection date for primary outcome measure)
Detailed Description:
The Jules Stein Eye Institute Ocular Melanoma Research Group is conducting cytogenetic studies of choroidal melanoma to improve the screening of biopsy samples of choroidal melanoma through cytogenetic analysis. Our goal is to identify molecular probes that specifically target regions of chromosomes that undergo changes characteristic of metastatic choroidal melanoma.
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients who have been diagnosed with ocular melanoma, and underwent melanoma treatment at our facility.
Criteria

Inclusion Criteria:

  1. Patient with diagnosis of ocular melanoma
  2. Patient with local treatment plan for ocular melanoma- plaque brachytherapy or enucleation
  3. Patient 18 years of age or older
  4. Archival enucleation specimens with diagnosis of ocular melanoma

Exclusion Criteria:

  1. Patient who refuses local melanoma treatment
  2. Patient who refuses to participate in this study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00344799

Contacts
Contact: Tara A McCannel, MD, PhD 310-206-7484 tmccannel@jsei.ucla.edu
Contact: Brenda Rangel 310 794-9962 Brangel@jsei.ucla.edu

Locations
United States, California
Jules Stein Eye Institute Recruiting
Los Angeles, California, United States, 90095
Contact: Brenda Rangel    310-794-9962    Brangel@jsei.ucla.edu   
Sponsors and Collaborators
Jonsson Comprehensive Cancer Center
Investigators
Principal Investigator: Tara M McCannel, MD, PhD Jules Stein Eye Institute, UCLA
Study Director: Bradley R Straatsma, MD, JD Jules Stein Eye Institute, UCLA
Study Chair: Lynn Gordon, MD, PhD Jules Stein Eye Institute, UCLA
Study Chair: Ben Glasgow, MD Jules Stein Eye Institute, UCLA
Study Chair: Nagesh P Rao, PhD UCLA Pathology and Laboratory Medicine
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Jonsson Comprehensive Cancer Center
ClinicalTrials.gov Identifier: NCT00344799     History of Changes
Other Study ID Numbers: UCLA IRB#04-12-084 
Study First Received: June 26, 2006
Last Updated: July 5, 2016
Health Authority: United States: Institutional Review Board

Keywords provided by Jonsson Comprehensive Cancer Center:
Choroidal Melanoma
Choroidal Malignant Melanoma
Ocular Melanoma
Uveal Melanoma

Additional relevant MeSH terms:
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas

ClinicalTrials.gov processed this record on September 26, 2016